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Abstract
Background: Renal cell carcinoma (RCC) is an adult malignancy with 2:1 men-to-women ratio, which implies the
possible role of sex hormones in RCC carcinogenesis. One of the predominant sex hormones in women before
menopause, 17-β-estradiol (or E2), may regulate RCC growth by cellular mechanisms that are still not fully understood.
Methods: The expression levels of E2 receptors (ER1 and ER2) were determined in different RCC cell lines. The DNA
damage response induced by E2 was determined by a DNA double-strand break marker γH2AX. To study the possible
effect of E2 on oxidative stress response, RCC cells were stained with 2,7-dichlorofluorescein diacetate and analyzed by
flow cytometry. Upregulation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) ser40 phosphorylation in response to
oxidative stress was detected by immunoblotting. Finally, annexin V/propidium iodide (PI) double staining assay was
used to determine E2-induced cellular apoptosis.
Results: Variable expression of ER1 and ER2 were found in the RCC cell lines studied (786-O, A498, and ACHN),
in which ACHN and A498 showed highest and lowest ER expression, respectively. In A498 cells, E2 induced DNA
double-strand breaks with positive staining of γH2AX. On the other hand, the level of reactive oxidative species
were elevated in ACHN cells after E2 treatment. The E2-induced oxidative stress also induced the Ser40 phosphorylation
and nuclear translocation of Nrf2. Finally, we also demonstrated that E2 induced apoptosis as revealed by annexin V/PI
double staining.
Conclusions: In this study, we demonstrated the cellular effects of E2 on DNA repair, ROS production as well as Nrf2
activation, and apoptosis in RCC cell lines. Together these cellular alterations may contribute to the reduced viability of
RCC cells following E2 treatment.
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Background
Renal cell carcinoma (RCC) is the most common solid
neoplasm of the kidney in adult human. This kidney
cancer exhibits a 2:1 male-to-female ratio with a better
survival rate in younger women [16]. Thus, there appear
to be hormonal effects on the development, progression,
and treatment of RCC [31, 33].
In RCC, altered chemosensitivity mediated by 17-β-
estradiol (E2) has been reported, so adjuvant therapy with
E2 is possible as in other human diseases [24, 45]. The
molecular mechanisms of the action of E2 in RCC cells
have been reported in recent years [8, 10, 13, 43, 45].
However, diverse genetic alterations are linked to renal
cancer progression and to our ability to predict its risk
[13, 23]. Targeted therapies incorporating inhibitors of the
vascular endothelial growth factor (VEGF) pathway is
the major treatment for patients with metastatic RCC
[18, 20, 49]. For example, anti-angiogenic drugs such
as sunitinib can nullify alterations in the microvascu-
lar properties of some human cancers [35]. This inhibition
reduces tumor vascularization, and leads to tumor shrink-
age. Clinically, cellular adaptations to VEGF-targeted anti-
angiogenic therapy might induce drug resistance in RCC
after transient disease stabilization, which limits the thera-
peutic efficacy of this approach and has been the major
problem for this treatment. Therefore, a rational and effi-
cacious treatment regimen for treating patients with RCC
is needed [4, 14].
E2, is known to exert a protective effect beyond its
classical endocrine role in several malignant diseases in-
cluding neurodegenerative disorders, esophageal cancers,
colorectal cancers, lung injuries, and coronary artery dis-
eases [11, 40, 42, 46]. Many cellular functions can be im-
proved by treatment with E2 alone or in combination
with its receptors [3, 25]. For example, E2 can induce an
increase in sensitivity to oxidative DNA damage through
an ER-dependent pathway [28]. Moreover, the oxidative
stress has been correlated to the phosphorylation of nu-
clear factor (erythroid-derived 2)-like 2 (Nrf2) at Ser40
[5, 29]. Therefore, the aim of this study was to under-
stand whether E2 might induce different cellular effects
on RCC cells. Briefly, changes in DNA repair mecha-
nisms, oxidative stress response, and viability were deter-
mined to evaluate the altered cellular effects.
Methods
Cell culture and genetic characteristics of RCC cell lines
The incubation condition and clinical status of three
RCC cell lines (ACHN, 786-O, and A498) were based on
information disclosed on the website (https://www.atc-
c.org) of the American Type Culture Collection (Manassas,
VA, USA). Their genetic characteristics are known from
previous reports [9, 47]. In experiments that involved treat-
ment with a specific chemical agent (or target hormone),
subconfluent cell cultures were incubated with the indi-
cated concentrations of E2 (E8875, Merck, Darmstadt,
Germany) for the indicated times as our previous report
[8]. Control cells were treated only with the solvent di-
methyl sulfoxide (DMSO).
Immunodetection of estrogen receptors and Nrf2 from
RCC cells
The protein levels of two estrogen receptors (ERs), ER1
and ER2, in RCC cells were determined by western blot
analysis. For this, protein extracts of each RCC cell line
were prepared with Pro-prep Protein Extraction Solution
(iNtRON Biotechnology, Seongnam, South Korea) ac-
cording to the manufacturer’s protocol with minor mod-
ifications. Briefly, the cell lysate was centrifuged for
10 min at 12,000 g to remove cellular debris. When ana-
lyzing the different protein fractions from the cytoplasm
and nuclei, the different cellular compartments were ex-
tracted and separated using NE-PER Nuclear and Cyto-
plasmic Extraction Reagents (Thermo Fisher Scientific,
Rockford, IL, USA) according to the manufacturer’s in-
structions. Each protein concentration was determined
using a BCA Protein Assay (Thermo Fisher Scientific).
When performing western blotting, protein lysates were
separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis and transferred to polyvinylidene difluor-
ide (PVDF) membranes. Then, each PVDF membrane was
incubated with primary antibodies (anti-ER1, ab37438 and
anti-ER2, ab3576; both from Abcam, Cambridge, MA,
USA) for 1 h and then for another 1 h with horseradish
peroxidase-labeled secondary antibody (L3012 for goat
anti-rabbit IgG; Signalway Antibody, College Park, MD,
USA) at room temperature. Target signals were exposed
and enhanced using Western Lightning Plus-ECL
Enhanced Luminol reagent (PK-NEL105, PerkinElmer,
Waltham, MA, USA). In addition, the total Nrf2 and its
phosphorylated form at Ser40 (phospho S40) in different
cellular compartments were determined using specific
antibody (ab62352 and ab76026, respectively; Abcam)
from 10 μg aliquots of individual proteins. Target signals
were amplified using the VECTASTAIN ABC-AmP kit
(AK-6602, Vector Laboratories, Burlingame, CA, USA).
The level of glyceraldehyde 3-phosphate dehydrogenase
(anti-GAPDH antibody; AM4300, Life Technologies,
Carlsbad, CA, USA) was determined as a loading
control for whole-cell lysates. An anti-α-tubulin anti-
body (sc-5286, Santa Cruz Biochemicals, Dallas, TX, USA)
was used as an internal control for cytoplasmic protein
levels, and lamin A/C (anti-lamin A/C antibody; sc-7292,
Santa Cruz Biochemicals) was used as an internal control
for nuclear protein levels. Images of immunoblots were
captured using a FluorChem FC2 system (Alpha Innotech,
Santa Clara, CA, USA). Cell lysates of two breast cancer
cell lines (T47-D and MCF-7) gifted from Prof. Shih-Ming
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Huang (Department and Graduate Institute of Biochemis-
try, National Defense Medical Center, Taiwan) served as
positive controls for ER1 and ER2.
Assay for the formation of phosphorylated histone H2AX
(γ-H2AX) foci
After incubation for 24 h of 5 × 104 cells per well, DNA
double strand breaks (DSBs) were induced in A498 cells
using etoposide as described in our previous report [17]
and observed in the presence or absence of E2. The abil-
ity to repair DSBs was determined by staining with an
anti-γ-H2AX antibody using an OxiSelect DNA Double
Strand Break Staining Kit (Cell Biolabs, San Diego, CA,
USA) according to the manufacturer’s instructions with
some minor changes. Briefly, cells were allowed to re-
cover by removing the DSB inducer for the indicated
time; the exposed DSBs (shown as γ-H2AX foci) appeared
as green fluorescence and nuclei were counterstained with
4′,6-diamidino-2-phenylindole. These fluorescent images
were all detected using an Olympus IX70 fluorescence
microscope (Olympus, Tokyo, Japan).
Detection of intracellular oxidative stress by flow
cytometry
Intracellular oxidative stress induced by E2 treatment
was determined by flow cytometry using 2′,7′-dichlor-
fluorescein-diacetate (DCFH-DA) as a sensitive nonfluo-
rescent precursor dye according to a published standard
procedure [1]. Cells were seeded on 6-well plates at
1.25 × 105 cells per well and cultured overnight as our
previous report [8]. Then, cells were treated with E2
(7 or 28 μM) for 24 h and incubated with 50 μM
DCFH-DA for 20 min in an incubator following an
appropriate wash with phosphate-buffered saline (PBS).
Cells were treated without E2 (DMSO alone) as a negative
control or with 1 mM H2O2 for 30 min as a positive con-
trol. Cells were then washed again with PBS, incubated
with 0.25 % trypsin- ethylenediaminetetraacetic acid for
1 min, and then quenched with minimum essential
medium with 10 % fetal bovine serum to stop trypsini-
zation. Detached cells were collected by centrifuging at
500 g for 5 min and resuspended in PBS. The fluores-
cence was determined by Flowcytometer FACSCalibur
(BD Biosciences, Franklin Lakes, NJ, USA), with excita-
tion at 480 nm and emission at 525 nm.
Detection of apoptosis
To identify apoptosis-positive cells, cells were stained with
an Annexin V/propidium iodide (PI) double staining
assay, with a fluorescein isothiocyanate (FITC) Annexin V
Apoptosis Detection Kit I (BD Biosciences), according to
the manufacturer’s protocol. Cells with various treatments
were washed with buffer (20 mM Tris pH 7.4, 150 mM
NaCl, 1 mM CaCl2) after incubation for 15 min in binding
buffer containing 5 μL of Annexin V–FITC and 5 μL
of PI at room temperature in the dark. Finally, fluor-
escent images of Annexin V–FITC binding and PI
incorporation were detected using the previous fluor-
escence microscope.
Results
Diverse expression levels of ERs in different RCC cell lines
Three RCC cell lines (ACHN, 786-O, and A498) were
cultured to detect the expression levels of ER1 and ER2
by western blot analysis (Fig. 1). Among these three cell
lines, ACHN cells expressed the highest protein levels of
ERs and A498 had the lowest expression, as reported
previously for mRNA levels [8]. Therefore, these two
RCC cell lines were subsequently analyzed for following
cellular effects.
Induction of DNA repair by E2 in A498 cells
A498 cells (low expressions of ERs, wild-type p53, and
VHL-null) had different properties of DNA repair under
E2 treatment. As shown in Fig. 2, over 90 % (37 of 40)
cells with active DNA repair were observed with green
fluorescence for γH2AX under E2 treatment; whereas,
less percentage of cells (44 %, 18 of 41) showed
fluorescence-positive in the etoposide-treated group. This
indicated that E2 could improve DNA repair, even though
this RCC cell line had low expression levels of the ERs.
Induction of oxidative stress by E2 in ACHN cells
Reactive oxygen species (ROS), known to reflect oxida-
tive stress, can cause significant damage to cell struc-
tures [33]. E2-induced ROS levels in ACHN cells (high
ERs, wild-type p53, and VHL-positive) were detected
using the DCFH-DA probe. As shown in Fig. 3, ACHN
cells showed an increased trend in intracellular ROS
levels when cells were treated with E2 (28 μM) for 24 h
compared with the DMSO-treated negative control cells.
Fig. 1 Immunodetection of estrogen receptors in cell lines of renal
cell carcinoma by Western blots. Protein lysates were prepared from
cell lines of renal cell carcinoma (ACHN, 786-O, and A498) and breast
cancer (T47-D and MCF-7), which served as positive controls. GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) was the internal
control. ER1 estrogen receptor 1, ER2 estrogen receptor 2
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In addition, activation of the Nrf2 transcription factor
was observed (Fig. 4). Briefly, increased phosphorylation
of nuclear Nrf2 (1.3 folds, in comparing to the cells
treated with DMSO only) were detected in ACHN cells
treated with E2 (28 μM), using immunoblot analysis.
Augmentation of apoptosis by E2 in ACHN cells
We next analyzed the apoptotic effects of E2 in ACHN
cells by detecting Annexin V-positive cells. As shown in
Fig. 5, ACHN cells treated with E2 (28 μM) could induce
the higher binding rates (70 %, 7 of 10 E2 (10 nM)- and
75 %, 3 of 4 E2 (28 μM)-treated cells) of Annexin V to
phosphatidyl serine at the surface of each cell. Conversely,
only 10 % (2 of 20) cells shown Annexin V-positive in the
DMSO-treated control group.
Discussion
Although the number of approved treatments for pa-
tients with advanced RCC continues to grow, additional
work is still needed to delineate the optimal target drug
or combination of agents for each subtype of this cancer
[36]. The therapeutic management of RCC is mainly
guided by the cancer stage and the degree of tumor dis-
semination, which affect the prognosis for patients dir-
ectly [7]. Regardless of the clinic availability of the novel
targeted therapeutics, and the favorable outcomes, how-
ever, complete or durable responses have been only
rarely noted. Nearly all treated patients even now will
develop drug resistance to any targeted treatment. Ap-
proximately 70 % of patients respond to therapy initially
and the remaining 30 % show primary resistance (intrin-
sic resistance) [6, 15]. The 70 % of patients who show
Fig. 2 DNA repairing ability of A498 cells with treatments of etoposide
and E2. A498 cells treated respectively with a etoposide (50 μM) alone
or b etoposide (50 μM) and E2 (70 nM). Green, γH2AX-positive cells;
blue, DAPI (4′,6-diamidino-2-phenylindole. The scale bar
represented the 50 μm. E2, 17-β-estradiol
Fig. 3 Induction of oxidative stress by E2. Reactive oxidative species
(ROS) formation in ACHN cells were detected by flow cytometry
(28 μM E2, orange line). DCFH-DA-pretreated cells as ROS-positive
were incubated with 50 μM DCFH-DA for 30 min at 37 °C. Blue line,
0.1 % DMSO (negative control); red line, 1 mM H2O2 (positive
control). E2, 17-β-estradiol
Fig. 4 Phosphorylation of nuclear Nrf2 by E2. Cytoplasm and
nuclear extracts were respectively isolated from ACHN cells. Each
compartment was immunodetected with antibody raised against
phospho Nrf2 (Ser40), lamin A/C (for nuclear control), and α-tubulin
(for cytosol control). Each protein level relative to individual control
was determined by densitometry and shown on the bottom of each
band. E2, 17-β-estradiol
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initial response, durable responses are rare, and acquired
resistance (extrinsic resistance) to treatment develops in
almost all of them in a median of 6–15 months [6, 15, 32].
However, it remains a challenge in the effective treatment
of RCC and suggests that effective therapies for RCC need
to be improved [12].
Autophagy mediated by E2 might have inhibited the
growth rate of ACHN cells in the present study [8]. In
addition, the activities of ERs have been correlated with
those of VHL and p53 in many studies [2, 19, 41].
Therefore, the genetic status of VHL and p53 expres-
sions of RCC cells should be considered when E2 is ap-
plied to treat RCC. p53-mediated transcription pathways
are involved in ER-related pathways [26]. Loss of VHL
may attenuate the DNA-damage response and result in
the persistence of DSBs [27]. In the present results,
A498 cells expressing wild-type p53 but with no VHL
expression could repair etoposide-induced DNA damage
in the presence of E2. The increased numbers of
γH2AX-positive A498 cells implied that lower levels of
ERs would not decrease their DNA repair capacity and
that E2 treatment could facilitate repair of the DNA
breaks even the cells were in the absence of VHL ex-
pression. This was similar to the conclusions of other
authors who reported that complexes of E2 with ER1 or
ER2 modulated the expression of many genes, including
those involved in DNA repair [3, 22, 25, 39]. Moreover,
the decreased DSBs would be obvious in the ACHN cells
with wild type VHL expression. Here, we also found that
ACHN cells expressed high levels of ERs. This might in-
dicate that ACHN cells might be sensitive to E2
treatment and that this could induce many other cellular
effects. This perspective also arose in other reports
showing that E2 might be correlated to the development
of this cancer [40, 45].
The highly conserved mechanism of autophagy is es-
sential when cells are under stress, including that in-
duced by ROS [44]. We reported previously that
autophagosomes were observed in ACHN cells in the
presence of E2 [8]. Sobočanec et al. and Zhu et al. re-
cently reported that E2 could mediate some antioxidant
enzymes via the Nrf2–Keap1 pathway [37, 48]. It will be
agreed with our data which demonstrate an increased
ROS under the E2 treatment. Here, we found that E2
could induce ROS production in ACHN cells. These E2-
induced ROS might activate the Nrf2 pathway to reduce
the oxidative stress and induce genotoxicity [30, 38].
Subsequently, sequential cell responses, autophagy, and
apoptosis changed the fate of the ACHN cells. These
findings were confirmed by the expression of activated
nuclear Nrf2, a key transcription factor that regulates
antioxidant defenses [21]. We found increased phos-
phorylation of Nrf2 in the nuclei of E2-treated ACHN
cells, which might cause a delay in proliferation and
induce apoptosis, similar to other cancers [34]. Taken
together, our results indicate that Nrf2 activation may
be necessary for this E2-induced autophagy and apop-
tosis. Combination therapy with E2 and target thera-
peutic agents may be a safe and potential practice
clinically to improve the tolerance and treatment dur-
ation of target therapy.
Conclusions
Adjuvant therapy with sex hormones could be beneficial
in many human diseases [8, 24]. Here, we demonstrated
the cellular effects of E2 on DNA repair, ROS produc-
tion as well as Nrf2 activation, and apoptosis in RCC cell
lines. It implies that these cellular alterations may con-
tribute to the reduced viability of RCC cells following E2
treatment.
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